Navigation Links
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Date:1/18/2008

INDIANAPOLIS, Jan. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company strongly objects to implications in a New York Times article published Thursday that the company has suppressed results of negative clinical trials.

The story, based on a separate article in The New England Journal of Medicine (NEJM), cited Prozac and Lilly as high-profile examples of how the industry purportedly suppresses negative clinical trial data. Not only was the Times' story inaccurate when it comes to Prozac -- the NEJM article didn't identify a single Prozac study as unpublished -- but it also likely created a strong false impression with readers that Lilly suppresses data.

Lilly is an industry leader in being transparent with our clinical trial data. We are committed to publicly disclosing medical research results -- whether favorable or unfavorable to a Lilly medicine -- in an accurate, objective and balanced manner in order for our customers to make more informed decisions about our products.

In December 2004, Lilly was widely recognized as the first pharmaceutical company to voluntarily launch a clinical trials registry, where we post the results of all Lilly sponsored registration clinical trials for all of our marketed products dating back to 1994, and all clinical trials for marketed products since December 2004.

In addition, the two Cymbalta studies listed in an appendix to the NEJM article as "unpublished" have, in fact, been published in peer-reviewed journals. The results of HMAT-A and HMAQ-B were published twice -- first in the Autumn 2002 issue of Psychopharmacology Bulletin, and again in the Primary Care Companion Journal of Clinical Psychiatry in 2003. In addition, these studies were presented at one or more medical congresses that require peer review of abstract submissions and they also have been available to the general public on LillyTrials.com since 2004.

The authors of the NEJM article decided not to count studies as "publish
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. CNS Response Announces Fiscal Third Quarter 2007 Results
2. Response Genetics Reports Second Quarter 2007 Financial Results
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
5. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
6. New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
9. Triage study challenges notions of emergency medical response to disaster
10. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)..., part of Life Technologies Corporation (NASDAQ:LI...h and discovery solutions, today announced that it... the SOLiD™ System, has been named the Life ...entist, a leading scientific publication focused o...ement of the first-ever Life Science Innovation of...
(Date:12/3/2008)...nd secondhand smoke, an estimated ten percent of p...f a developing baby to harmful cigarette byproduct...000 newborns each year and poses a significant hea...s kind, a team of researchers has completed a glob... better understand the fetal health risks from smo...
(Date:12/3/2008)...FirstCall/ -- GlaxoSmithKline,(LSE/NYSE: GSK ) ...ating to a,pending lawsuit in the previously anno...ding shares of common stock of Genelabs Technologi...n cash without interest and less any,required wit...completion of the tender offer that there not be,...
(Date:12/3/2008)...-- Cellectricon, a leading,provider of screening ...,signing of a collaborative agreement with The Aut...s of advanced automated systems for cell culture, ...pplications. Under the agreement,TAP will co-deve...ectricon,s,next generation high throughput ion ch...
Breaking Biology Technology: Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 2Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 3
...ely following the progress of the Health Insuranc...electronic health records for the last eight month... dentist with a small healthcare business, I have ...all a "stakeholder" in this exciting and promising...re important than my job, I am a husband and fathe...
...- BellBrook Labs has been awarded two federal gran...opment of its enzyme screening product. , ,The bio... screening tools for the drug-therapy market, said...l Business Innovation Research (SBIR) awards. Hig...ct millions of biochemical, genetic, or pharmacolo...
...- An education research team at the University of...he MacArthur Foundation to study the impact of d...acy. , ,MacArthur,s total $50 million investment ...cts of the digital revolution and its educational ...actually trying to do, with this grant to us, is e...
...eek in Austin , Dallas , and Boston , getting a...art ups. (Yep, you guessed it, the search for DEMO...h of what I saw was quite impressive. It was also ...lley . , ,Where Silicon Valley is at the apex of ...dership in IT systems management. In Dallas, I fou...
Other Biology Technology:Careful with that electronic health record, Mr. Leavitt 2Careful with that electronic health record, Mr. Leavitt 3Careful with that electronic health record, Mr. Leavitt 4Grants worth $800,000 help BellBrook Labs develop products 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3What makes Silicon Valley so different? 2What makes Silicon Valley so different? 3What makes Silicon Valley so different? 4
(Date:12/4/2008)...en want younger women, often touting their intelli...earch at Gothenburg University and Oxford Universi...en and women choose partners. , Research in the ...theories about how men and women choose their part... place more emphasis on attractive appearance, whe...
(Date:12/3/2008)...nes, deputy executive director of the Internationa...tlook 2008" Dec. 9 at Rice University,s Baker Inst...ch questions as: Is the world facing a supply crun...at type of post-Kyoto policy framework might stabi... and what impact might such a policy framework hav...
(Date:12/3/2008)...re. December 3, 2008. The first 5-year forest inve... is now available to the public: Oregon,s Forest R...d Analysis Report. , Here are some key findings ... 30 million acres; about half of Oregon,s total la...ng converted to other uses particularly near urban...
(Date:12/3/2008)...-- A Duke University study suggests that evolution... the dogs depend on an energy-efficient style of f...eir prey, cats seem to have evolved a profoundly i...e or bird in slow motion. , "It is usually assum...said Daniel Schmitt, a Duke associate professor of...
Breaking Biology News(10 mins):Myth about 'dirty old men' supported by science 2'World Energy Outlook' to be presented at Rice University Dec. 9 2Forest inventories in Oregon include more than trees 2Forest inventories in Oregon include more than trees 3Dogs chase efficiently, but cats skulk counterintuitively 2Some Iraq War Vets Suffer Breathing Problems 19978 1Some Iraq War Vets Suffer Breathing Problems 19978 2Some Iraq War Vets Suffer Breathing Problems 19978 3Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 1Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Low intensity case management cuts COPD related hospital visits in half 19966 1Low intensity case management cuts COPD related hospital visits in half 19966 2
...omparison of equipment that can analyze the expres...etic "fingerprint," suggests these different micro...t. , Published in the May 2005 issue of Nature Me... of information generated by these systems might a...systems are used by many different laboratories. ,...
...he University of Liverpool have discovered how the...f Europeans resistant to HIV. Scientists have know...etic mutation (known as CCR5-delta32) that prevent...system but have been unable to account for the hig... low levels in areas bordering the Mediterranean. ...
...of North Carolina at Chapel Hill is one of five cl...e National Institutes of Health to study why good ...ring the next seven years, the Drug-Induced Liver ...have suffered severe liver injury caused by prescr...al supplements, alternative medicines and herbals....
... microarray analyses result in many differentially...for the biological process of interest. In order t...publications from MEDLINE were identified in which... with specific keywords were co-mentioned. , MEDLI... keywords were generated and validated. PubMed IDs...
Other Biology News:Different microarray systems more alike than previously thought 2Different microarray systems more alike than previously thought 3First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2UNC launches study of liver injury caused by drugs 2
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein
MOUSE ANTI BOVINE TROPONIN I
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG
Normal donkey serum collected from healthy normal donkeys.
Biology Products: